Is MK-677 a peptide?

01 · Continued

What MK-677 means: more detail

Researchers describe it as a growth hormone secretagogue. A secretagogue is a substance that causes cells to release another substance. Here, the term refers to growth hormone release. It describes an effect, not a chemical class.

This distinction matters when a heading groups several compounds together. A page label or a shared biological effect cannot establish that all listed compounds are peptides.

02

What the classification study shows

A 2005 study by Holst and colleagues compared MK-677 with peptide compounds at the ghrelin receptor. The authors explicitly classified MK-677 as nonpeptide. Their laboratory tests measured receptor binding and signals within cells.

Different compounds can act on the same receptor. That shared target does not mean they have the same structure, effects in people, or safety profile. These laboratory results do not establish a treatment benefit.

Earlier research by Patchett and colleagues, published in 1995, used the names L-163,191 and MK-0677. It studied hormone release in rat cells and dogs. Oral administration in those experiments is a study detail. It does not establish human benefit or a safer route.

03

Keep the compound separate from the product

The name on a label does not show that a product matches the material used in a study. Evidence must fit the exact substance, formulation, route, and population.

Some records name ibutamoren mesylate. For example, the hip-fracture trial and FDA compounding table use that name. Keep those records tied to the material they identify. Do not assume that another formulation or finished product is equivalent.

In its September 23, 2025, notice, FDA reported finding undeclared ibutamoren in Agebox iKids Growth Day Formula. That finding concerns the tested product. It does not establish what any other product contains.

The same notice states that ibutamoren is not FDA approved. It also says that its safety and effectiveness have not been established. The notice was rechecked on September 11, 2026. This is a dated U.S. statement, not a review of laws in every country.

04

What the safety evidence can tell you

FDA identifies a potential congestive heart-failure risk for ibutamoren mesylate in certain patients. Heart failure means the heart cannot pump blood as well as the body needs. FDA links this concern to a trial in people recovering from hip fracture.

The 2011 report by Adunsky and colleagues describes a randomized, placebo-controlled trial in 123 older hip-fracture patients. Its outcomes included physical function and a blood marker related to growth hormone. The report gives results at 24 weeks.

The authors report that the trial stopped early after a heart-failure safety signal. A rise in the blood marker did not produce improvement in most measures of physical function.

These findings do not give a reliable risk rate for a different population or product. They also do not show that other people are safe. Calling a compound nonpeptide does not remove the need for safety evidence.

05

Where this answer stops

The classification answer is clear: MK-677 is a nonpeptide. Claims about muscle growth, recovery, anti-aging effects, or safe use need separate evidence that fits the exact claim.

This guide checked the listed study abstracts and FDA records. It did not review the full study methods, all adverse-event tables, or complete conflict disclosures. It does not establish the identity or quality of a product sold online.

For the broader definition and the role of chemical structure, read the linked guide about what peptides are.